<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">iron-chelation-therapy-parkinsons-disease</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">Deferiprone</td>
<td>Phase II/III</td>
</tr>
<tr>
<td class="label">Deferasirox</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">Combined chelation + neuroprotective</td>
<td>Phase I</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Key Monitoring</td>
</tr>
<tr>
<td class="label">Deferiprone</td>
<td>CBC with neutrophil count</td>
</tr>
<tr>
<td class="label">Deferasirox</td>
<td>Liver function, serum creatinine</td>
</tr>
<tr>
<td class="label">Deferoxamine</td>
<td>Audiology, ophthalmology</td>
</tr>
</table>
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">iron-chelation-therapy-parkinsons-disease</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">Deferiprone</td>
<td>Phase II/III</td>
</tr>
<tr>
<td class="label">Deferasirox</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">Combined chelation + neuroprotective</td>
<td>Phase I</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Key Monitoring</td>
</tr>
<tr>
<td class="label">Deferiprone</td>
<td>CBC with neutrophil count</td>
</tr>
<tr>
<td class="label">Deferasirox</td>
<td>Liver function, serum creatinine</td>
</tr>
<tr>
<td class="label">Deferoxamine</td>
<td>Audiology, ophthalmology</td>
</tr>
</table>
Iron Chelation Therapy for Parkinson's Disease represents a promising disease-modifying approach that targets iron accumulation in the brain, a well-documented pathological feature of PD. Iron dysregulation contributes to oxidative stress, ferroptosis, and neuronal death in the substantia nigra, making iron chelation a rational therapeutic strategy["1"][2].
The most advanced clinical program is the FAIRPARK-II trial evaluating deferiprone, which demonstrated reduced brain iron levels and slower disease progression in patients with early Parkinson's disease["1"][2]. This page provides comprehensive coverage of the scientific rationale, clinical evidence, and current development status of iron chelation therapy specifically for PD.
Iron is essential for normal cellular function, including mitochondrial energy production, neurotransmitter synthesis, and myelin formation. The brain requires precise regulation of iron levels, as both deficiency and excess can impair neuronal function. Iron homeostasis is maintained through:
In Parkinson's disease, iron accumulates selectively in the substantia nigra pars compacta (SNc), where dopaminergic neurons are located[3]. This accumulation is thought to occur through several mechanisms:
The iron accumulation pattern in PD differs from other neurodegenerative diseases:
Two forms of iron are particularly relevant to PD pathogenesis:
Ferrous iron (Fe²⁺): The reactive form that can participate in Fenton reactions, generating hydroxyl radicals that cause oxidative damage to lipids, proteins, and DNA.
Ferric iron (Fe³⁺): The less reactive form that can be stored in ferritin. However, when ferritin becomes overwhelmed, excess ferric iron can be reduced to ferrous iron.
Iron chelation is thought to provide neuroprotection through multiple mechanisms[4]:
By removing chelatable iron, chelation therapy prevents Fenton chemistry and reduces hydroxyl radical formation:
Fe²⁺ + H₂O₂ → Fe³⁺ + OH• + OH⁻ (Fenton reaction)
Chelators bind ferrous iron, preventing its participation in this reaction.
Ferroptosis is an iron-dependent form of programmed cell death characterized by lipid peroxidation. Iron chelation can prevent ferroptosis by removing the iron necessary for lipid ROS generation[5].
Iron overload impairs mitochondrial Complex I activity, reducing ATP production and increasing ROS. Chelation therapy may preserve mitochondrial function.
Iron-laden microglia exhibit a more pro-inflammatory phenotype. Iron reduction may decrease microglial activation and associated neuroinflammation.
Neuromelanin in the substantia nigra can become iron-saturated, losing its protective buffering capacity. Iron chelation may restore neuromelanin's protective function.
Early studies: Deferoxamine was first explored in PD in the 1980s-1990s[6][7]:
Deferiprone is an oral iron chelator that crosses the blood-brain barrier more effectively than deferoxamine[8]. It is the most studied chelator in PD clinical trials.
Design: Randomized, double-blind trial in 40 patients with early PD Results:
Design: Larger trial with 186 early PD patients[1][2] Dosing: 20 mg/kg/day oral deferiprone Results:
Deferasirox is an oral iron chelator with improved tolerability[9]:
Iron chelation may be most effective when combined with other neuroprotective strategies:
Iron chelation may provide neuroprotection while DBS addresses motor symptoms.
Iron chelation therapy may be most beneficial for:
New iron chelators in development include:
Successful development requires better biomarkers:
Future therapy may be tailored based on:
Iron chelation therapy represents a promising disease-modifying approach for Parkinson's disease. The FAIRPARK-II trial demonstrated that deferiprone can reduce brain iron levels and slow disease progression in early PD patients[1][2]. Ongoing trials are refining patient selection, optimizing dosing, and exploring combination approaches. Iron chelation addresses a fundamental pathological process in PD and represents one of the few therapies with direct disease-modifying potential based on mechanism.